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Objective: Among patients with symptomatic carotid artery stenosis, carotid artery stenting (CAS) is associated with
a higher risk of periprocedural stroke or death than carotid endarterectomy (CEA). Uncertainty remains whether the
balance of risk changes with time since the most recent ischemic event.
Methods:We investigated the association of time between the qualifying ischemic event and treatment (0-7 days, 8-14 days,
and >14 days) with the risk of stroke or death within 30 days after CAS or CEA in a pooled analysis of data from individual
patients randomized in the Endarterectomy vs Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-
3S) trial, the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) trial, and the International Carotid
Stenting Study (ICSS). Data were analyzed with a ﬁxed-effect binomial regression model adjusted for source trial.
Results: Information on time of qualifying event was available for 2839 patients. In the ﬁrst 30 days after intervention,
any stroke or death occurred signiﬁcantly more often in the CAS group (110/1434 [7.7%]) compared with the CEA
group (54/1405 [3.8%]; crude risk ratio, 2.0; 95% conﬁdence interval, 1.5-2.7). Patients undergoing CEA within the
ﬁrst 7 days of the qualifying event had the lowest periprocedural stroke or death rate (3/106 [2.8%]). Patients treated
with CAS in the same period had a 9.4% risk of periprocedural stroke or death (13/138; risk ratio CAS vs CEA: 3.4; 95%
conﬁdence interval, 1.01-11.8; adjusted for age, sex, and type of qualifying event). Patients treated between 8 and 14 days
showed a periprocedural stroke or death rate of 3.4% (7/208) and 8.1% (19/234), respectively, for CEA and CAS. The
latest treatment group had 4% complications in the CEA group (44/1091) and 7.3% in the CAS group (78/1062).
Conclusions: The increase in risk of CAS compared with CEA appears to be greatest in patients treated within 7 days of
symptoms. Early surgery might remain most effective in stroke prevention in patients with symptomatic carotid artery
stenosis. (J Vasc Surg 2013;57:619-26.)3The timing of revascularization of symptomatic internal
carotid artery stenosis has changed over the last decade.
Contrary to the recommendations from the 1960s and
1970s, carotid endarterectomy (CEA) is now performed as
soon as possible after the index symptom. The rapidly
declining beneﬁt of surgery with the delay of treatment
results from the high percentage of recurrent ischemic events
in the ﬁrst 7 to 14 days after the qualifying event.1-5 The
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620 Rantner et al March 2013might be necessary to minimize periprocedural complica-
tions in CAS. However, any delay in treatment must be
balanced against the risk of a recurrent ischemic event.
The study at hand investigated the association between
outcome and timing of treatment in a pooled analysis of
individual patient data from the Symptomatic Severe
Carotid Stenosis trial (EVA-3S), the Stent-Protected
Angioplasty versus Carotid Endarterectomy (SPACE) trial,
and the International Carotid Stenting Study (ICSS).
METHODS
EVA-3S (NCT 00190398), SPACE (ISRCTN
57874028), and ICSS (ISRCTN 25337470) were random-
ized clinical trials with blinded outcome adjudication. In all
three trials, patients with recently symptomatic moderate or
severe carotid stenosis ($50% reduction of the lumen diam-
eter according to the method used in the North American
Symptomatic Carotid Endarterectomy Trial [NASCET]8),
who were considered equally suited for either procedure,
were randomly allocated to undergo treatment by stenting
or endarterectomy.9-11 The pooled analysis of individual
patient data was prospectively agreed on at the design stage
of these trials.12 The primary outcome event for the present
analysis of the pooled data was the combination of any stroke
or death occurringwithin 30 days after treatment. Secondary
outcome eventswere disabling stroke or death and any stroke
occurring during this period. The analysis was done per
protocol, including only those patients who received the
randomly allocated treatment as the ﬁrst initiated revascular-
ization procedure after randomization and in whom the date
of the qualifying event (deﬁned as the last ischemic event ipsi-
lateral to the relevant carotid artery prior to randomization:
retinal ischemia, hemispheric transient ischemic attack
[TIA], or hemispheric stroke) or the interval between the
qualifying event and treatment was known.
The date of the qualifying event was ascertained at
baseline in EVA-3S and ICSS. The date of the qualifying
event was not prospectively collected in the SPACE trial
at baseline; for the pooled analysis, the date of the
qualifying event (or, if the exact date was unknown,
whether or not randomization and treatment took place
within 7 days or within 14 days of the qualifying event)
was retrieved where possible. Patients with missing data
concerning delay between qualifying event and treatment
were excluded from the analysis.
Statistical analysis. The pooled data were ﬁrst
analyzed with a ﬁxed-effect binomial regression model
including only source trial terms as covariables, to obtain
crude estimates of risk ratio (RR) with 95% conﬁdence
interval (CI) of major outcome events between CAS and
CEA, depending on the interval between the qualifying
event and treatment (0-7, 8-14, and >14 days). For
adjusted risk calculation, age, sex, and type of qualifying
event (retinal ischemia, TIA, or stroke) were additionally
included in the regression model. The interaction between
delay from qualifying event and treatment effect (CAS vs
CEA) was formally tested by including a multiplicative
interaction term in the model. Furthermore, we calculatedthe RRs between each time stratum in both treatment arms
and early CEA (within 7 days of the qualifying event),
which was deﬁned as referenced standard procedure.
RESULTS
The pooled Carotid Stenting Trialists’ Collaboration
(CSTC) analysis included 3433 patients (1725 in the
CAS group and 1708 in the CEA group) who were
randomized and followed up in the three contributing
trials. In total, 1679 patients underwent stenting and
1645 patients received endarterectomy as their randomly
allocated revascularization procedure. Information on
delay of treatment from qualifying event was not avail-
able for 483 patients from the SPACE study (245
patients received CAS and 238 patients were treated by
surgery) and for two patients from ICSS (both treated
by CEA). Therefore, a total of 2839 patients (n ¼
1434 in the CAS group and n ¼ 1405 in the CEA
group) remained for per-protocol data analysis concern-
ing outcome under the inﬂuence of timing of treatment
(Figure).
The median delay between the most recent ipsilateral
event and treatment was 29 days in the stent group (inter-
quartile range [IQR], 14-65) and 32 days in the endarterec-
tomy group (IQR, 15-71). Patient characteristics at baseline
were comparable in the two treatment groups (Table I).
A total of 244 patients (8.6%) received treatment within
7 days after the index event (n ¼ 138 in the CAS group
and n ¼ 106 in the CEA group), 442 patients (15.6%)
had treatment between 8 and 14 days after the qualifying
event (CAS: n¼ 234; CEA: n¼ 208), whereas the majority
of patients (CAS: n ¼ 1062; CEA: n ¼ 1091) were treated
more than 14 days after the qualifying ischemic event.
Supplementary Table I, online only, shows that demo-
graphic data of the patients, vascular risk factors, preexisting
vascular disease, degree of stenosis, and severity of neuro-
logic deﬁcit (measured by the modiﬁed Rankin score) did
not change in a relevant way with time until treatment.
The proportion of patients with hemispheric stroke as the
qualifying event was lower among patients treated within
7 days (CAS: 31%; CEA: 32%) than in the groups treated
for 8 to 14 days (CAS: 53%; CEA 47%) and >14 days
(CAS: 48%, CEA: 49%) after the qualifying event, but there
were no signiﬁcant differences between treatment groups
across the three time strata. In the ﬁrst 30 days after inter-
vention, any stroke or death occurred signiﬁcantly more
often in the CAS group (110/1434 [7$7%]) compared
with the CEA group (54/1405 [3.8%]; crude RR, 2.0;
95% CI, 1.5-2.7; pc2 < .001). Type and number of major
outcome events, as well as information on stroke severity
and territory in the three time strata, are given in
Supplementary Table II, online only.
Table II lists the RRs and number of major outcome
events in the three strata of time between qualifying event
and treatment adjusted only for source trial. The risk of any
stroke or death within 30 days of treatment (the primary
outcome event) was lowest in the early CEA (0-7 days)
group (3/106 [2.8%]). Early CAS had a stroke or death
Fig. Flow diagram of patients included in the meta-analysis.
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of 3.79 (95% CI, 1.1-13.1; P ¼ .03). With a delay of
8 to 14 days, CEA had a stroke or death rate of 3.4%
(7/208) compared with 8.1% (19/234) in the CAS group
(RR, 2.42; 95% CI, 1.0-5.7; P ¼ .04). The latest CEA
group (>14 days) showed a perioperative stroke or death
rate of 4.0% (44/1091) compared with 7.3% (78/1062)
in the stenting group (RR, 1.82; (95% CI, 1.3-2.6;
P ¼ .001) Results were similar with any stroke within
30 days of treatment as the outcome event. There was
no signiﬁcant difference in the two treatment groups in
the occurrence of periprocedural disabling stroke or death.
The test for interaction between delay from qualifying
event and the treatment effect of CAS vs CEA was not
signiﬁcant for any of the three outcome measures.
Additional adjustment for age, sex, and type of qualifying
event for time strata analysis did not inﬂuence the RRs in
a relevant way (Supplementary Table III, online only).
Proposing that early CEA (0-7 days) might be the
treatment of choice because of the lowest periprocedural
rate of complications, we created a multivariate model,
adjusted for age, sex, source trial, and type of qualifying
event, with early CEA as the reference procedure. Here
we saw that the 9.4% risk of stroke or death in the early
CAS group corresponds to an RR of 3.4 (95% CI, 1.01-
11.8) compared with early CEA. The adjusted RR declined
to 2.68 (95% CI, 0.8-8.9) for carotid stenting between8 to 14 days and to 2.58 (95% CI, 0.8-8.0) for CAS after
14 days. Later CEA had a higher risk for perioperative
stroke or death compared with early surgery, without
reaching statistical signiﬁcance, however (8-14 days:
adjusted RR, 1.16; 95% CI, 0.3-4.4; >14 days: adjusted
RR, 1.38; 95% CI, 0.4-4.4). Table III summarizes the
adjusted RRs for all three end points.
DISCUSSION
Timing of surgery signiﬁcantly inﬂuences the beneﬁt in
patients with symptomatic internal carotid artery stenosis.
Analysis from the pooled data fromNASCET and the Euro-
pean Carotid Surgery Trial (ECST) showed that surgery
was most effective when performed within the ﬁrst 2 weeks
after a qualifying ischemic event.13 Recent literature even
supports CEA in the very early stage after neurologic symp-
toms.14-18 Over the last decade, it became apparent that the
early days after cerebral ischemia were most hazardous for
the patient. The percentage of recurrent ischemic events is
notably high in the ﬁrst 2 weeks with 12% to 15%.3,5,18
Therefore, carotid revascularization should be carried out
as soon as possible to prevent a recurrent stroke.
Outcome of CAS and CEA depending on the
timing of treatment after the most recent ischemic
event. Several trials focused on the safety and efﬁcacy of
CAS compared with CEA as gold standard in the treatment
of symptomatic stenosis in the internal carotid artery.19-24
Table I. Baseline data of the combined trial population
CAS
(n ¼ 1434)
CEA
(n ¼ 1405)
Age at randomization, mean (SD), years 70.2 (9.0) 70.2 (9.2)
Male, No. (%) 1032 (72%) 1012 (72%)
History of diabetes, No. (%) 335 (23.4%) 331 (23.6%)
History of hypertension, No. (%) 1025 (71.5%) 1012 (72.0%)
History of hypercholesterolemia, No. (%)a 661a (46.1%) 681a (48.5%)
Any smoking history (current or past), No. (%) 887 (61.9%) 876 (62.3%)
History of coronary heart disease, No. (%) 347 (24.2%) 351 (25.0%)
History of peripheral artery disease, No. (%)a 173a (12.1%) 161a (11.5%)
Degree of ipsilateral carotid stenosis, No. (%)b
Moderate (50%-69%) 245b (17.1%) 230b (16.4%)
Severe (70%-99%) 1189b (82.9%) 1175b (83.6%)
Contralateral severe carotid stenosis ($70%) or occlusion, No. (%)b 205b (14.3%) 202b (14.4%)
Transient ischemic attack 491 (34.2%) 486 (34.6%)
Retinal ischemia 261 (18.2%) 243 (17.3%)
Hemispheric stroke 670 (46.7%) 664 (47.3%)
History of stroke before most recent event, No. (%)a 184a (12.8%) 176a (12.5%)
Days elapsed between most recent ipsilateral ischemic event
and treatment, median (IQR)c
29 (14-65) 32 (15-71)
Treatment within 7 days of most recent eventc 138 (9.6%) 106 (7.5%)
Treatment within 14 days of most recent eventc 372 (25.9%) 314 (22.3%)
CAS, Carotid artery stenting; CEA, carotid endarterectomy; EVA-3S, Endarterectomy vs Angioplasty in Patients with Symptomatic Severe Carotid Stenosis;
ICSS, International Carotid Stenting Study; IQR, interquartile range; NASCET, North American Symptomatic Carotid Endarterectomy Trial; SPACE, Stent-
Protected Angioplasty versus Carotid Endarterectomy; SD, standard deviation.
Percentages exclude missing data. P values are not included because there is no statistically signiﬁcant difference between time groups.
aData collected in EVA-3S and ICSS only.
bDegree of stenosis measured by NASCET method or equivalent noninvasive method.
cThe date of the most recent ipsilateral ischemic event before randomization was not collected in the SPACE trial initially, but for the meta-analysis, these dates
(or if the exact date was unknown, whether or not randomization and treatment took place within 14 days of the qualifying event) were retrieved where available.
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time management in CAS. Topakian et al6 investigated the
outcome of 77 consecutive patients who underwent CAS
for $60% symptomatic carotid stenosis within 180 days of
TIA or moderate stroke (modiﬁed Rankin scale score #3).
The 30-day composite end point for stroke (7.8%) and
death of any cause (1.3%) was 9.1%. The authors saw that
patients suffering from periprocedural complications
underwent stenting signiﬁcantly earlier compared with
patients with uneventful treatment (median delay,
1.5 weeks vs 3.2 weeks; P ¼ .004). In multivariate logistic
regression analyses, delay of treatment <2 weeks (odds
ratio, 22.4; 95% CI, 2.2-223.4; P ¼ .008) remained
predictive for the 30-day outcome.6 However, in a series of
320 patients undergoing CAS for symptomatic stenosis,
Gröschel et al7 saw that timing was not signiﬁcantly asso-
ciated with periprocedural complications, regardless of
whether this variable was dichotomized (<14 days and
$14 days), separated into IQRs, or analyzed as a contin-
uous variable. The pooled data from SPACE, EVA-3S, and
ICSS represent the largest series of patients receiving either
CAS or CEA for symptomatic carotid artery stenosis in trial
conditions. We found that CEA within 1 week of the latest
ischemic event was the treatment with the lowest number
of periprocedural complications. Stenting, however, was
most hazardous when performed early. This supports the
ﬁndings of Topakian et al.6 The fact that the risk of CAS
declines with delay to the ischemic event is also apparent in
our study population, with the P value showing a cleartrend, without reaching statistical signiﬁcance. Surgery, on
the other hand, was more harmful in the later period after
the ischemic event but also without reaching statistical
signiﬁcance.
The CSTC recently reported that age had a relevant
inﬂuence on the outcome after CAS. In patients younger
than 70 years, the estimated 120-day risk of stroke or death
was 50 (5.8%) of 869 patients in the carotid stenting group
and 48 (5.7%) of 843 in the CEA group (RR, 1.00; 95% CI,
0.68-1.47). In patients 70 years or older, the estimated risk
with carotid stenting was twice that with CEA (103/856
[12.0%] vs 51/865 [5.9%]; 2.04; 95% CI, 1.48-2∙82; inter-
action P ¼ .0053; P ¼ .0014 for trend).21
Outcome in the adjusted model. The crude compar-
ison between CAS and CEA in the three timing strata
showed, as has already reported elsewhere, that surgery
had better results in the treatment of symptomatic internal
carotid artery stenosis.25 The analysis at hand shows
that this is true independent from timing of treatment.
However, we see in our study population that the risk of
CAS is especially high in the early days after the qualifying
ischemic event. The outcome was worst in patients treated
by CAS within 7 days after the latest cerebral ischemia.
Patients who underwent early surgery, however, had the
best periprocedural outcome, independent from age, sex,
type of qualifying neurologic event, and source trial. From
this, we conclude that rapid surgery still remains the gold
standard for treatment of symptomatic internal carotid
artery stenosis.
Table II. Risks for different end points depending on the timing of treatment (0-7 days, 8-14 days, and thereafter) and
treatment modality
CEA, No. (%) CAS, No. (%) Crude RR (95% CI) P value
Stroke or death
0-7 days 3 (2.8%) 13 (9.4%) 3.79 (1.1-13.1) .03
8-14 days 7 (3.4%) 19 (8.1%) 2.42 (1.0-5.7) .04
>14 days 44 (4.0%) 78 (7.3%) 1.82 (1.3-2.6) .001
Disabling stroke or death
0-7 days 1 (0.9%) 7 (5.1%) 6.40 (0.8-51.0) .08
8-14 days 3 (1.4%) 7 (3.0%) 2.28 (0.6-8.7) .23
>14 days 28 (2.6%) 34 (3.5%) 1.35 (0.8-2.2) .22
Any stroke
0-7 days 3 (2.8%) 13 (9.4%) 3.79 (1.1-13.1) .03
8-14 days 7 (3.4%) 18 (7.7%) 2.27 (1.0-5.4) .06
>14 days 41 (3.8%) 74 (7.0%) 1.86 (1.3-2.7) .001
CAS, Carotid artery stenting; CEA, carotid endarterectomy; CI, conﬁdence interval; RR, risk ratio.
RRs are calculated within the time strata only adjusted for source trial. The CEA group represents the reference group.
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ICSS, and EVA-3Sdrandomized patients between 2001
and 2009, at a time when the concept of early surgery
was not fully implemented worldwide. This might be
the explanation for the small number of patients who
received treatment close to the qualifying event (only
9.6% of CAS patients and 7.5% of CEA patients within
1 week and 16.3% and 14.8% in the CAS and CEA group
within 2 weeks of last symptoms). Therefore, statistical
power to show a signiﬁcant interaction between timing
of treatment and relative risks of stroke or death between
CAS and CEA was low. Incorporating data from the
Carotid Revascularization Endarterectomy versus Stent-
ing Trial (CREST), which is foreseen in the future, may
help to answer this question.26
Importantly, the timing of treatment was not subject to
randomization in any of the three contributing trials.
Therefore, we needed to exclude a treatment bias in the
way that neurologically stable patients were treated earlier
and those with severe impairment were treated in a later
period of time. Supplementary Table I, online only,
summarizes type and severity of the qualifying neurologic
event in the three timing groups. The type of qualifying
event differed signiﬁcantly between patients treated within
the ﬁrst week of the event and those treated later, with
a lower proportion of patients with hemispheric stroke
treated in the early period. On the other hand, the severity
of neurologic impairment, measured by the modiﬁed Ran-
kin scale, was comparable in the treatment groups and both
treatment techniques. Adjustment for the type of the qual-
ifying event in the multivariate model did not change our
results in a relevant way.
Timing of treatment was not a primary focus at base-
line examination in the SPACE trial. As a consequence,
timing data for 483 patients at baseline are missing in
this trial. These patients had to be excluded for the analysis
at hand. To allow a timing analysis, a retrospective datacollection in the SPACE trial was performed in time inter-
vals (treatment within 7 days after the most recent
ischemic event, treatment between 8 and 14 days, and
treatment thereafter). This consecutively inﬂuenced
timing analysis in the whole study population. Receiver-
operating characteristic curves with timing as continuous
parameter did not allow the identiﬁcation of a cutoff value
because we had a broad CI due to the small number of
complications.
Operator experience and its inﬂuence on the outcome
is still a matter of controversial discussion. Many authors
suggest that the inexperience of interventional centers
participating in the large trials was responsible for the
high complication rate in the stenting arms. This fear was
diluted for the EVA-3S data. In this trial, patients who
were treated by the most experienced interventionalists
(>50 carotid procedures) had the highest risk for stroke
or death at 12.2%. Interventionalists who had done 50 or
fewer procedures reached a periprocedural stroke or death
rate of 11.0%. Best results were achieved by physicians who
were still in procedural training at 7.1%. The differences did
not reach statistical signiﬁcance (P ¼ .49).27 In contrast, in
the latest update of a Cochrane Systematic Review of
randomized trials, the odds ratio for periprocedural stroke
or death in CAS vs CEA was higher in trials requiring
lower numbers of pretrial procedures than in trials
requiring a higher level of experience, but not signiﬁcantly
so.28 A detailed analysis on the role of experience in the
risk of complications with CAS in all three contributing
trials is ongoing.
Our data suggest that CEA remains treatment of ﬁrst
choice and can be performed safely within the ﬁrst week
of ischemic symptoms in neurologically stable patients. In
contrast, the risk of CAS appears to be especially high in
this early phase and declines thereafter. Because we do
know that these early days after the initial ischemic event
carry the highest risk for a recurrent ischemia, a delay in
Table III. Risks for different end points depending on timing of treatment (0-7 days, 8-14 days, and thereafter) and
treatment modality adjusted for age, sex, source trial, and type of qualifying event
No. (%) RR (95% CI)
Stroke or death
CEA
0-7 days (ref) 3 (2.8%) 1
8-14 days 7 (3.4%) 1.16 (0.3-4.4)
>14 days 44 (4.0%) 1.38 (0.4-4.4)
CAS
0-7 days 13 (9.4%) 3.44 (1.0-11.8)
8-14 days 19 (8.1%) 2.68 (0.8-8.9)
>14 days 78 (7.3%) 2.58 (0.8-8.0)
Disabling stroke or death
CEA
0-7 days (ref) 1 (0.9%) 1
8-14 days 3 (1.4%) 1.49 (0.2-14.1)
>14 days 28 (2.6%) 2.86 (0.4-20.9)
CAS
0-7 days 7 (5.1%) 5.73 (0.7-45.8)
8-14 days 7 (3.0%) 3.11 (0.4-25.0)
>14 days 34 (3.5%) 3.93 (0.5-28.4)
Any stroke
CEA
0-7 days (ref) 3 (2.8%) 1
8-14 days 7 (3.4%) 1.16 (0.3-4.4)
>14 days 41 (3.8%) 1.29 (0.4-4.1)
CAS
0-7 days 13 (9.4%) 3.43 (1.0-11.7)
8-14 days 18(7.7%) 2.54 (0.8-8.5)
>14 days 74 (7.0%) 2.45 (0.8-7.7)
CAS, Carotid artery stenting; CEA, carotid endarterectomy; CI, conﬁdence interval; RR, risk ratio.
Early surgery (0-7days) was deﬁned as reference procedure.
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for the patients at risk. CEA remains most effective in
stroke prevention.
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at www.jvascsurg.org.DISCUSSIONDrEvaRzucidlo (Lebanon,NH).DrCambria hadmentioned in
his presidential address thatmaybe it’s howwe’re treatingpatientswith
carotid stents that’s leading to the high stroke rate. I wonder if you
could just comment about the embolic protection, if we should beusing more ﬂow reversal and whether stent grafting would decrease
the risk of stroke for those patients when we want to treat them early.
Dr Gustav Fraedrich. As you know, in the three European
trials, there were different regimens regarding the use of protection
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626 Rantner et al March 2013devices. We analyzed these parameters and couldn’t identify an
inﬂuence on the results.
Dr Wesley Moore (Los Angeles, Calif). I’d like to congratu-
late you on an excellent presentation and bringing to our attention
an extremely important observation with regard to the early differ-
ential complication rate between CAS and CEA.
In your table, you listed not only the comparative complication
rates within the ﬁrst 7 days but also in several time intervals after
that. You went through that rather quickly and I couldn’t see the
exact numbers, but as I looked at it, that differential complication
rate favoring carotid endarterectomy also persisted in 7 to 14, 14
to 28, and so forth. Could you comment and perhaps elaborate
on that a little bit? Again, these are extremely important data.
Dr Fraedrich. As I showed at the beginning, we published
the whole data in 2010 in The Lancet, and there was a signiﬁcant
difference in favor of endarterectomy that of course still persists in
the subgroups. But what we could show is that this difference is
signiﬁcantly most pronounced in the ﬁrst 7 days. It continues to
exist in the 14-day group and later on, but it’s more pronounced
in the ﬁrst week.
It is our policy, as in the majority of large vascular centers, to
treat symptomatic patients as early as possible. In our institution,
they are treated within 1 or 2 days after onset of symptoms. I believe
that this is the group that really proﬁts from revascularization. So,
the risk of treatment within the ﬁrst 7 days is of special importance.Dr John Ricotta (Washington, DC). I just wanted to follow
up on that a little bit. This is great data and congratulations on
a good analysis.
I understand that the Rankin score for CAS and CEA are the
same, but I want to ask a little different question regarding these
data and whether you could look at them to see whether the
severity of the stroke that the patient had before surgery
impacted the postprocedure intervention stroke rate. One of
the things we’re being pushed to do is to try to determine in
these patients how severe a stroke are you willing to operate
on within a few days. I know that you didn’t analyze it in this
situation, but I just wonder if you could comment on that and
whether you think your data set could help give us some infor-
mation about that.
Dr Fraedrich. Our policy today is on patients with stroke
with a Rankin score below 2 to 3, in particular when the neuro-
logical situation improves after the initial stroke. If the neurolog-
ical situation becomes worse, we perform a CT scan with regard
to the blood-brain barrier, and we tend not to operate on the
patient.
Dr Ricotta. I think that’s what we all do. I’m wondering
whether with the database that you have, you can give us some
better guidelines.
Dr Fraedrich. We were looking at that, but the data do not
allow to answer this question.
Supplementary Table I (online only). Baseline characteristics of patients according to the timing of treatment in three
groups (0-7 days, 8-14 days, and >14 days)
0-7 days 8-14 days >14 days
CAS
(n ¼ 138)
CEA
(n ¼ 106)
CAS
(n ¼ 234)
CEA
(n ¼ 208)
CAS
(n ¼ 1062)
CEA
(n ¼ 1091)
Age at randomization, mean (SD), years 68.9 (8.3) 69.3 (9.1) 70.3 (9.4) 69.9 (9.9) 69.7 (9.0) 69.8 (9.2)
Male, No. (%) 103 (74.6%) 80 (75.5%) 179 (76.5%) 160 (76.9%) 741 (69.8%) 781 (71.6%)
History of diabetes, No. (%) 38 (27.5%) 20 (18.9%) 58 (24.8%) 43 (20.7%) 239 (22.5%) 268 (24.6%)
History of hypertension, No. (%) 98 (71.0%) 85 (80.2%) 166 (70.9%) 145 (69.7%) 761 (71.7%) 782 (71.7%)
History of hypercholesterolemia, No. (%)a 52 (37.7%) 34 (32.1%) 103 (44.0%) 87 (41.8%) 506 (47.6%) 560 (51.3%)
Any smoking history (current/past), No. (%) 96 (69.6%) 65 (61.3%) 147 (62.8%) 130 (62.5%) 644 (60.6%) 681 (62.4%)
History of coronary heart disease, No. (%) 39 (28.3%) 36 (34.0%) 53 (22.6%) 57 (27.4%) 255 (24.0%) 258 (23.6%)
History of peripheral artery disease, No. (%)a 12 (8.7%) 11 (10.4%) 31 (13.2%) 25 (12.0%) 130 (12.2%) 125 (11.5%)
Degree of ipsilateral carotid stenosis, No. (%)b
Moderate (50%-69%) 27 (19.6%) 16 (15.1%) 50 (21.4%) 47 (22.6%) 168 (15.8%) 167 (15.3%)
Severe (70%-99%) 111 (80.4%) 90 (84.9%) 184 (78.6%) 161 (77.4%) 894 (84.2%) 924 (84.7%)
Contralateral severe carotid stenosis ($70%)
or occlusion, No. (%)b
17 (12.3%) 14 (13.2%) 27 (11.5%) 33 (15.9%) 161 (15.2%) 155 (14.2%)
Type of most recent ipsilateral ischemic
event before randomization, No. (%)
Transient ischemic attack 75 (54.3%) 53 (50.0%) 81 (34.6%) 79 (38.0%) 337 (31.7%) 352 (32.3%)
Retinal ischemia 18 (13.0%) 18 (17.0%) 31 (13.2%) 26 (12.5%) 212 (20.0%) 199 (18.2%)
Hemispheric stroke 43 (31.2%) 34 (32.1%) 123 (52.6%) 98 (47.1%) 504 (47.5%) 532 (48.8%)
Modiﬁed Rankin score at baseline, No. (%)c
0 63 (45.7%) 49 (46.2%) 103 (44.0%) 81 (38.9%) 506 (47.6%) 470 (43.1%)
1 43 (31.2%) 32 (30.2%) 64 (27.4%) 57 (27.4%) 274 (25.8%) 285 (26.1%)
2 24 (17.4%) 22 (20.8%) 45 (19.2%) 44 (21.2%) 192 (18.1%) 228 (20.9%)
3 7 (5.1%) 3 (2.8%) 17 (7.3%) 19 (9.1%) 62 (5.8%) 81 (7.4%)
4 1 (0.7%) 0 4 (1.7%) 2 (1.0%) 12 (1.1%) 15 (1.4%)
5 0 0 0 0 1 (0.1%) 3 (0.3%)
History of stroke before most recent
event, No. (%)a
13 (9.4%) 0 (9.4%) 35 (15.0%) 25 (12.0%) 136 (12.8%) 141 (12.9%)
CAS, Carotid artery stenting; CEA, carotid endarterectomy; EVA-3S, Endarterectomy vs Angioplasty in Patients with Symptomatic Severe Carotid Stenosis;
ICSS, International Carotid Stenting Study; NASCET, North American Symptomatic Carotid Endarterectomy Trial; SD, standard deviation.
Percentages exclude missing data. P values are not included because there is no statistically signiﬁcant difference between time groups.
aData collected in EVA-3S trial and ICSS only.
bDegree of stenosis measured by NASCET method or equivalent noninvasive method.
cModiﬁed Rankin scores at baseline may reﬂect nonstroke impairments; protocols of contributing trials excluded patients with disabling strokes.
Supplementary Table II (online only). Type and number of outcome events in the three time strata and treatment
groups
0-7 days 8-14 days >14 days
CAS
(n ¼ 138)
CEA
(n ¼ 106)
CAS
(n ¼ 234)
CEA
(n ¼ 208)
CAS
(n ¼ 1062)
CEA
(n ¼ 1091)
Any stroke or death 13 (9.4%) 3 (2.8%) 19 (8.1%) 7 (3.4%) 78 (7.3%) 44 (4%)
Disabling stroke or death 7 (5.1%) 1 (0.9%) 7 (3%) 3 (1.4%) 37 (3.5%) 28 (2.6%)
All-cause death 2 (1.4%) 0 3 (1.3%) 0 13 (1.2%) 8 (0.7%)
Any stroke 13 (9.4%) 3 (2.8%) 18 (7.7%) 7 (3.4%) 74 (7%) 41 (3.8%)
Stroke severity
Fatal stroke 0 0 2 (9.9%) 0 9 (0.8%) 5 (0.5%)
Disabling stroke 7 (5.1%) 1 (0.9%) 4 (1.7%) 3 (1.4%) 23 (2.2%) 20 (1.8%)
Nondisabling stroke 6 (4.3%) 2 (1.9%) 12 (5.1%) 4 (1.9%) 42 (4%) 17 (1.6%)
Stroke pathology
Ischemic stroke 13 (9.4%) 3 (2.8%) 16 (6.8%) 1 (2.9%) 69 (6.5%) 33 (3%)
Hemorrhagic stroke 0 0 2 (0.9%) 1 (0.5%) 5 (0.5%) 7 (0.6%)
Unknown pathology 0 0 0 0 0 1 (0.1%)
Stroke territory
Ipsilateral carotid 12 (8.7%) 3 (2.8%) 16 (6.8%) 6 (2.9%) 67 (6.3%) 38 (3.5%)
Contralateral carotid or vertebrobasilar 1 (0.7%) 0 1 (0.4%) 1 (0.5%) 6 (0.6%) 4 (0.4%)
Unknown territory 0 0 1 (0.4%) 0 1 (0.1%) 0
CAS, Carotid artery stenting; CEA, carotid endarterectomy.
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Supplementary Table III (online only). Risks for different endpoints depending on the timing of treatment (0-7 days,
8-14 days, and thereafter) and treatment modality
Carotid endarterectomy, No. (%) Carotid stenting, No. (%) Adjusted risk ratio (95% CI) P value
Stroke or death
0-7 days 3 (2.8%) 13 (9.4%) 4.00 (1.2-13.8) .03
8-14 days 7 (3.4%) 19 (8.1%) 2.27 (1.0-5.3) .06
>14 days 44 (4.0%) 78 (7.3%) 1.87 (1.3-2.7) .001
Disabling stroke
0-7days 1 (0.9%) 7 (5.1%) 6.41 (0.8-50.1) .08
8-14 days 3 (1.4%) 7 (3.0%) 2.30 (0.6e8.4) .25
>14 days 28 (2.6%) 34 (3.5%) 1.39 (0.9-2.3) .18
Any stroke
0-7days 3 (2.8%) 13 (9.4%) 4.00 (1.2e13.8) .03
8-14 days 7 (3.4%) 18 (7.7%) 2.12 (0.9-5.0) .09
>14 days 41 (3.8%) 74 (7.0%) 1.90 (1.3-2.8) .001
CI, Conﬁdence interval.
Risk ratios are calculated within the time strata adjusted for age, sex, source trial, and type of qualifying event. The carotid endarterectomy group represents the
reference group.
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